Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • CD4-Positive T-Lymphocytes
  • Dacarbazine
  • Lymphopenia
  • Melanoma

abstract

  • TMZ at this dose and schedule results in CD4(+) lymphopenia in a majority of patients that can result in OIs. Pneumocystis pneumonia prophylaxis should be considered for patients who develop sustained lymphopenia on TMZ.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.07.060

PubMed ID

  • 14726505

Additional Document Info

start page

  • 610

end page

  • 6

volume

  • 22

number

  • 4